公开(公告)号：US11129903B2

公开(公告)日：2021-09-28

申请号：US15202822

申请日：2016-07-06

申请人： REGENERON PHARMACEUTICALS, INC.

发明人： Julian Andreev ,  Nithya Thambi ,  Frank Delfino ,  Joel Martin ,  Gavin Thurston ,  Katherine Cygnar ,  Nicholas Papadopoulos

IPC分类号： A61K47/68 ,  C07K16/22 ,  C07K16/28 ,  C07K1/32 ,  C07K16/12 ,  C07K16/18 ,  C07K14/47 ,  C07K16/30 ,  A61P35/00 ,  C07K16/46 ,  A61K39/00 ,  C12N9/64 ,  C07K16/32

摘要： The present invention provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present invention can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the invention, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone. In other embodiments of the invention, the target molecule is a tumor associated antigen, and the simultaneous binding of the tumor associated antigen and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention causes or facilitates the targeted killing of tumor cells.

公开(公告)号：US11191844B2

公开(公告)日：2021-12-07

申请号：US15738801

申请日：2016-07-06

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Julian Andreev ,  Nithya Thambi ,  Frank Delfino ,  Joel Martin ,  Gavin Thurston ,  Katherine Cygnar ,  Nicholas Papadopoulos

IPC分类号： A61K47/68 ,  C07K16/22 ,  C07K16/28 ,  C07K16/32 ,  C07K16/18 ,  C07K14/47 ,  C07K16/30 ,  A61P35/00 ,  C07K16/46 ,  A61K39/00 ,  C12N9/64 ,  C07K16/12

摘要： The present disclosure provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present disclosure can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the disclosure, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present disclosure results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone. In other embodiments of the disclosure, the target molecule is a tumor associated antigen, and the simultaneous binding of the tumor associated antigen and the internalizing effector protein by the multispecific antigen-binding molecule of the present disclosure causes or facilitates the targeted killing of tumor cells.

公开(公告)号：US20220008548A1

公开(公告)日：2022-01-13

申请号：US17483588

申请日：2021-09-23

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Julian Andreev ,  Nithya Thambi ,  Frank Delfino ,  Joel Martin ,  Gavin Thurston ,  Katherine Cygnar ,  Nicholas Papadopoulos

IPC分类号： A61K47/68 ,  C07K16/22 ,  C07K16/28 ,  C07K16/32 ,  C12N9/64 ,  C07K16/12 ,  C07K16/18 ,  C07K14/47 ,  C07K16/30 ,  A61P35/00 ,  C07K16/46

摘要： The present invention provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present invention can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the invention, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone. In other embodiments of the invention, the target molecule is a tumor associated antigen, and the simultaneous binding of the tumor associated antigen and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention causes or facilitates the targeted killing of tumor cells.

公开(公告)号：US20190000984A1

公开(公告)日：2019-01-03

申请号：US15738801

申请日：2016-07-06

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Julian Andreev ,  Nithya Thambi ,  Frank Delfino ,  Joel Martin ,  Gavin Thurston ,  Katherine Cygnar ,  Nicholas Papadopoulos

IPC分类号： A61K47/68 ,  C07K16/28 ,  C07K16/22 ,  C07K16/30 ,  C07K16/32 ,  C12N9/64 ,  A61P35/00 ,  C07K16/46

摘要： The present disclosure provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present disclosure can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the disclosure, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present disclosure results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone. In other embodiments of the disclosure, the target molecule is a tumor associated antigen, and the simultaneous binding of the tumor associated antigen and the internalizing effector protein by the multispecific antigen-binding molecule of the present disclosure causes or facilitates the targeted killing of tumor cells.